Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

AMLX stock hub

Amylyx Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

AMLXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.6B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

AMLX

In the news

Latest news · AMLX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-63.3

P25 -105.6P50 -46.5P75 -3.1

ROIC-41.3

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All AMLX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

181

Groups with data

Currency

USD

Showing 181 of 181 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001658551
Company name	Amylyx Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	03237H101
Employees	136
Employees Change	13%
Employees Change Percent	10.57
Enterprise value	$1.4B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2022-01-07
Isin	US03237H1014
Last refreshed	2026-05-10
Market cap	$1.6B
Market cap category	Small-Cap
Price	$14.73
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	AMLX
Website	https://amylyx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-9.17%
FCF yield	-7.36%
P/B ratio	5.99x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-95.9M
Net Income	$-150.1M
Net Income Growth Years	1%
Profit Per Employee	$-1.1M
ROA	-38.79
Roa5y	-42.6
ROCE	-57.37
ROE	-63.26
Roe5y	-86.06
ROIC	-41.34

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	202.69%
Cagr3y	-20.25%
EPS Growth Quarters	5
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$293.6M
Cash	$279.8M
Current Assets	$285M
Current Liabilities	$16M
Debt	$5.6M
Debt Equity	$0.02
Equity	$273.2M
Liabilities	$20.4M
Long Term Assets	$8.6M
Long Term Liabilities	$4.5M
Net Cash	$274.1M
Net Cash By Market Cap	$16.74
Net Cash Growth	35.25%
Net Debt Equity	$-1
Tangible Book Value	$273.2M
Tangible Book Value Per Share	$2.46
WACC	3.67

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	17.85
Net Working Capital	$-9.6M
Quick ratio	17.53
Working Capital	$269.1M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-38.81%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	202.46%
200-day SMA	13.27
3Y total return	-49.28%
50-day SMA	15.41
50-day SMA vs 200-day SMA	50over200
All Time High	41.93
All Time High Change	-64.87%
All Time High Date	2023-01-30
All Time Low	1.58
All Time Low Change	835.24%
All Time Low Date	2024-06-17
ATR	0.9
Beta	-0.1
Beta1y	1.18
Beta2y	1.48
Ch YTD	21.94
High	15.46
High52	18.61
High52 Date	2026-04-17
High52ch	-20.83%
Low	14.51
Low52	4.2
Low52 Date	2025-05-14
Low52ch	250.71%
Ma50ch	-4.41%
Premarket Change Percent	1.65
Premarket Price	$15.45
Premarket Volume	76,240
Price vs 200-day SMA	11.02%
RSI	38.04
RSI Monthly	55.68
RSI Weekly	52.66
Sharpe ratio	1.89x
Sortino ratio	3.56
Total Return	-38.81%
Tr YTD	21.94
Tr1m	-9.47%
Tr1w	-8%
Tr3m	5.37%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	5
Analyst Price Target Top	$21.8
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.34
Operating Income	$-159.3M
Price target	$23
Price Target Change	$56.14
Price Target Change Top	$48

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	83,431,903%
Float Percent	75.04%
Net Borrowing	190,736,000
Shares Insiders	6.72%
Shares Institutions	85.09%
Shares Out	111,186,317
Shares Qo Q	0.66%
Shares Yo Y	38.81%
Short Float	17.78%
Short Ratio	13.31
Short Shares	13.34

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-147.5M
Average Volume	1,080,175.15x
Bv Per Share	2.46
CAPEX	$-127,000
Ch1m	-9.47
Ch1w	-8
Ch1y	202.5
Ch3m	5.37
Ch3y	-49.28
Ch6m	19.66
Change	-3.09%
Change From Open	-3.09
Close	15.2
Days Gap	0
Depreciation Amortization	467,000
Dollar Volume	27,874,595.4
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$-159.3M
EBITDA	$-158.8M
EPS	$-1.49
F Score	2
FCF	$-120.5M
FCF EV Yield	-8.84x
FCF Per Share	$-1.08
Financing CF	194,584,000
Fiscal Year End	December
Founded	2,014
Income Tax	$46,000
Investing CF	93,960,000
Ipr	-22.47
Iprfo	-29.86
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-03
Ma150	14.3
Ma150ch	2.99%
Ma20	16.67
Ma20ch	-11.62%
Net CF	168,909,000
Next Earnings Date	2026-08-06
Open	15.2
Optionable	Yes
Position In Range	23.16
Ppne	5,093,000
Pre Close	15.2
Price Date	2026-05-08
Ptbv Ratio	6
Relative Volume	1.75x
Share Based Comp	26,932,000
Tr6m	19.66%
Us State	Massachusetts
Volume	1,892,369

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does AMLX pay a dividend?

Capital-return profile for this ticker.

Performance

AMLX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns AMLX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+85.1%

Float: +75.0% of shares outstanding

Insider ownership

+6.7%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

AMLX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

38.0

Neutral momentum band

Price vs 200-day MA

+11.0%

50/200-day relationship not available

Beta (5Y)

-0.10

Less volatile than the market

Sharpe ratio

1.89

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About AMLX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current AMLX stock rating?

Amylyx Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full AMLX analysis?

The full report lives at /stocks/AMLX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for AMLX?

The latest report frames AMLX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the AMLX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.